Dynavax Technologies Corp - Company Profile
Powered by 
All the sales intelligence you need on Dynavax Technologies Corp in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Dynavax Technologies Corp fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Dynavax Technologies Corp.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Dynavax Technologies Corporation (Dynavax) is a commercial-stage biopharmaceutical company focused on developing and commercializing novel vaccines to protect against infectious diseases. The company's main activities include the development and manufacturing of vaccines, with a particular emphasis on utilizing innovative adjuvant technology. Dynavax's major product, HEPLISAV-B, is a hepatitis B vaccine approved for use in adults. The company is also advancing a pipeline of vaccine candidates, including those for shingles, Tdap, and plague. It serves healthcare providers and patients, offering solutions for the prevention of hepatitis B virus infections. The company operates in the US and Europe. Dynavax is headquartered in Emeryville, California, the US.
Headquarters
United States of America
Address
2100 Powell Street, Suite 720, Emeryville, California, 94608
Website
www.dynavax.com
Telephone
1 510 8485100
No of Employees
405
Industry
Pharmaceuticals and Healthcare
Revenue (2024)
$277.2M
Dynavax Technologies Corp premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Heplisav-B: an Adult Vaccine for Hepatitis B | Heplisav-B |
| Pipeline | |
| Z-1018: For the Prevention of Shingles in Adults Aged 50 Years and Older. | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Ownership Changes | In February, the company was acquired by Sanofi, a pharmaceutical company. |
| 2023 | Regulatory Approval | In February, the company received approval from Great Britain Marketing Authorization for HEPLISAV B. |
| 2021 | Regulatory Approval | In December, the company announced that, the vacciene developed by Biological E for Covid using its CpG 1018 Adjuvant recieved India DCGI approval for emergency use. |
Competitor Comparison
| Key Parameters | Dynavax Technologies Corp | Johnson & Johnson | Merck & Co Inc | Pfizer Inc | AstraZeneca Plc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United Kingdom |
| City | Emeryville | New Brunswick | Rahway | New York City | Cambridge |
| State/Province | California | New Jersey | New Jersey | New York | Cambridgeshire |
| No. of Employees | 405 | 138,200 | 73,000 | 81,000 | 96,100 |
| Entity Type | Private | Public | Public | Public | Public |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Scott Myers | Director; Chairman | Executive Board | 2021 | 58 |
| Ryan Spencer | Director; Chief Executive Officer | Executive Board | 2019 | 47 |
| Kelly MacDonald | Chief Financial Officer | Senior Management | 2021 | 41 |
| David F. Novack | Chief Operating Officer; Senior Vice President | Senior Management | 2026 | 63 |
| Jeff P. Coon | Chief Human Resources Officer | Senior Management | 2019 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer